D-PLEX 312 - Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection (SHIELD II)
Trial details
- Registry ID
- NCT04411199
- Drugs studied
- D-PLEX, Standard of Care (SoC)
TrialRedline tracks 4 clinical trials sponsored by PolyPid Ltd.: 3 Phase 3, 1 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| D-PLEX 312 - Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection (SHIELD II)NCT04411199 | D-PLEX, Standard of Care (SoC) | Completed | 2025-04-14Actual |
| D-PLEX 311: Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional InfectionNCT04233424 | D-PLEX, Standard of Care (SoC) | Completed | 2022-09-02Actual |
| D-PLEX 302: Efficacy and Safety of D-PLEX in the Prevention of Sternal Infection Post Cardiac SurgeryNCT03558984 | D-PLEX, Standard of Care | Terminated | 2022-10-24Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| D-PLEX 310: Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional InfectionNCT03633123 | D-PLEX, Standard of Care (SoC) | Completed | 2019-09-06Actual |
Names as written in the registry records.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Infection Rate as Measured by the Proportion of Subjects With an Surgical Site Infection (SSI) Event in the Population of Subjects With Target Incision Length >20 cm. After: Measure: Infection Rate as Measured by the Percentage of Subjects With SSI Event in the Target Incision Within 30 Days Post Index Surgery or Re-interventions or Death [for Any Reason] in the Population of Subjects With Target Incision Length >20 cm.
NCT03558984 · PolyPid Ltd.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Proportion of Participants With a Sternal Wound Infection Event. After: Measure: Number of Participants With a Sternal Wound Infection Event.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: To assess the anti-infective efficacy of D-PLEX over a period of 30 days post operation, by preventing surgical site infection (SSI), defined as superficial and deep infection, in the target incision(s), compared to the SoC treated control. Measure: Safety of D-PLEX in Prevention of Post Abdominal Surgery Measure: Safety of D-PLEX in Prevention of Post Abdominal Surgery Incisional. After: Measure: Infection Rate as Measured by the Proportion of Subjects With an Surgical Site Infection (SSI) Event in the Population of Subjects With Target Incision Length >20 cm.
Before: 800 participants (actual). After: 975 participants (actual).
NCT03558984 · PolyPid Ltd.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Sternal Wound Infection (SWI) Rate. After: Measure: Proportion of Participants With a Sternal Wound Infection Event.
NCT03558984 · PolyPid Ltd.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Sternal Wound Infection Rate. After: Measure: Sternal Wound Infection (SWI) Rate.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Infection rate as measured by the proportion of subjects with abdominal incisional infection event. After: Measure: The Combined Infection and Mortality Rate Within 30 Days Post Index Surgery.
Before: 200 participants (actual). After: 202 participants (actual).
NCT03558984 · PolyPid Ltd.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Sternal Wound Infection rate. After: Measure: Sternal Wound Infection Rate.